Compare Repligen Corporation Common Stock (RGEN) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Under Armour Inc Class A — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Under Armour Inc Class A trades at $4.65 (market cap $2.08B). The key difference: Repligen Corporation Common Stock is far larger — about 5.4× Under Armour Inc Class A's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Under Armour Inc Class A for 19 Days on average.
| RGEN | UA | |
|---|---|---|
Market Cap | $11.14B | $2.08B |
Volume | 1,259,263 | 2,142,599 |
Sector | Health | Consumer Cyclical |
52-Week High | $194.57 | $7.88 |
52-Week Low | $102.87 | $3.96 |
Typical Hold Time | 0 Days | 19 Days |
Enterprise Value | $11.02B | $3.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Under Armour (UA) trades at $4.76, down 0.63% with a bullish technical signal despite negative profitability metrics. The company reported mixed quarterly earnings with two beats and one miss, while revenue declined to $4.9B in 2026 with a net loss of $492M. Analyst sentiment is divided with 40% buy ratings, though recent news highlights revenue guidance cuts and competitive pressures.
The outlook remains challenging with persistent revenue declines and negative margins offset by attractive valuation multiples. Investment opportunity lies in potential turnaround execution, while risks include sustained consumer demand weakness and execution missteps in a highly competitive athletic apparel market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
